Latest filing published 04 Mar 2026 for Kymera Therapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Bruce N. Jacobs, listed as finance chief, appears in our data through filings on Kymera Therapeutics, Inc. shares, published by SEC (Form 4). The record holds 57 filings, for trades running from 3 March 2021 to 4 March 2026.
Every open-market trade on record is a sale: 33 sales worth €8.4M. Other entries cover 5 share grants and 19 option exercises. 2026 to date brings no purchases and 7 sales.
Most recently, on 4 March 2026, the filings show an open-market sale worth €152k in Kymera Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations